Although LVADs were initially developed as a bridge to cardiac transplantation, they are now routinely used as destination therapy or bridge to transplant candidacy given the shortage of organ donors. 5, 6 Despite advances in both LVAD design and treatment protocols, neurological complications, specifically ischemic and hemorrhagic strokes, remain as major causes of morbidity and mortality in patients requiring LVAD support.
Stroke

May 2018
neurological events can range from transient mild symptoms to chronic debilitation necessitating institutionalization or even death. 9 Previously published retrospective analyses have attempted to define the incidence of and risk factors for stroke with LVAD use. Published rates of ischemic and hemorrhagic strokes vary from 0% 15 up to 48.3%, 9 depending on the specific LVAD model, antithrombotic regimen, and patient population studied. The cause of this increased stroke risk is multi-factorial. The most common causes of these events are cardioembolism and primary cerebral hemorrhage in the setting of anticoagulation; less frequent causes are ischemia caused by low perfusion, septic emboli, and air embolism. 16, 17 In prior studies, risk factors for post-LVAD stroke have included longer duration of heart failure, more severe heart failure, atrial fibrillation, hypertension, vascular disease, acquired von Willebrand factor deficiency, elevated preoperative total bilirubin, decreased pre-and postoperative albumin and sodium, postoperative infection, female sex, diabetes mellitus, and prior stroke. 11, 18, 19 However, these associations have rarely been distinguished by type of stroke, despite our knowledge of distinct underlying pathophysiologies, limiting the information available to aid in the development of approaches to preventive therapy.
The continued growth and application of LVAD therapy will be promoted by efforts to lower the incidence of and improve outcomes after post-LVAD strokes. Ischemic and hemorrhagic post-LVAD strokes have different pathophysiologies and may have different impacts on outcome. Limited data exist to guide prediction of post-LVAD stroke subtypes.
11,12
Here, we present an analysis of the stroke risk and outcome of 183 consecutive patients who underwent implantation of the HM II LVAD (Thoratec [now Abbott], Atlanta, GA) at Brigham and Women's Hospital between 2007 and 2016. We aimed to determine the incidence of ischemic and hemorrhagic strokes, their association with stroke risk factors, and their effect on mortality.
Methods
From 2007 to 2016, 183 patients with chronic heart failure underwent implantation of an HM II LVAD: 97 implants were bridge to transplant, 72 destination therapy, and 14 bridge to candidacy. Data are collected prospectively on all patients with LVADs implanted at Brigham and Women's Hospital and reported using Interagency Registry for Mechanically Assisted Circulatory Support. Requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to Interagency Registry for Mechanically Assisted Circulatory Support at grantstuddard@uabmc. edu. This study met the American Heart Association Journals' implementation of the Transparency and Openness Promotion, as well as the Health Insurance Portability and Accountability Act guidelines, and was approved by the Institutional Review Board. Clinical data and laboratory results were analyzed from prospectively collected data including age, sex, body mass index, hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, prior stroke, transient ischemic attack (TIA), peripheral vascular disease, chronic kidney disease, dialysis dependence, hemoglobin, and international normalized ratio (INR).
Clinical care was standardized for all LVAD HM II patients. All but 9 patients were treated with warfarin targeting an INR of 2 to 3.5. INRs were collected for each patient from the time of LVAD implant to either explant (with or without transplant) or death. Percent time in therapeutic range (TTR) was calculated by totaling the days in therapeutic range between each pair of INR values and dividing by the total days on warfarin therapy, using the Rosendaal Method, to account for differences in patient treatment time. 20 TTR values were unavailable for 9 patients: 2 of whom were transplanted and 7 of whom died during their initial LVAD admission. All patients were also treated with aspirin 81 or 325 mg daily. Stroke was defined according to the Interagency Registry for Mechanically Assisted Circulatory Support 4, 21 and American Heart Association/American Stroke Association guidelines for a new global neurological deficit, 22 including TIA and ischemic or hemorrhagic strokes based on full neurological examination by neurologists. We excluded all subdural and epidural hematomas from this study to avoid any trauma-related pathology. All patients with strokes underwent neuroimaging with noncontrast computed tomography at the time of the initial acute neurological deterioration and were treated according to institutional standards for stroke management. The primary outcome of our study was proportion of patients with post-LVAD stroke. The secondary outcome was post-LVAD mortality.
Statistical Analysis
Clinical characteristics and laboratory data were compared among groups using the unpaired Student 2-tailed t test for continuous variables and the χ 2 test for categorical variables. Univariable logistic regression analysis was used to assess the association of clinical variables with post-LVAD overall strokes, ischemic strokes, and hemorrhagic strokes. To follow a hypothesis-generating approach, we used stepwise forward Cox regression models to identify the important predictors of post-LVAD stroke with an entry-level P value <0.10 within a multivariable model. The purpose of this approach is to allow statistical decision-making to include or exclude predictors of the outcome of interest in the final regression model, based merely on the statistical significance irrespective of the biophysiological mechanism. Kaplan-Meier analysis was used to demonstrate the effect of statistically significant predictors of post-LVAD stroke. With post-LVAD mortality as a secondary outcome, univariable and multivariable logistic regression models were built to assess the association of clinical and laboratory variables with risk of death. Statistical significance was defined as 2-tailed P value <0.05. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).
Results
From 2007 to 2016, 183 patients underwent implantation of an HM II LVAD at Brigham and Women's Hospital. The median age was 57 years, 80% were male, 12% had a history of stroke, and 9% had a history of TIA (Table 1) . Sixty-eight percent of patients had concomitant atrial fibrillation.
During a median follow-up time of 400 days (interquartile range, 145-821 days), 39 patients (21%) suffered 48 strokes and 18 patients (10%) suffered 19 TIAs. Strokes were classified as ischemic, hemorrhagic, or ischemic with hemorrhagic transformation. Twenty-four patients (13%) suffered 28 ischemic strokes. Of these patients, 5 (20.8) had hemorrhagic transformation, 4 (16.7%) had a second ischemic stroke event, and 4 (16.7%) suffered a hemorrhagic stroke event during the follow-up period. Thirteen patients (7.1%) had a single ischemic stroke without secondary hemorrhage. Nineteen patients (10.3%) suffered 20 hemorrhagic strokes. With suspension of anticoagulation after hemorrhagic stroke, no thromboembolic events or pump failures were seen, and only 1 delayed recurrent hemorrhage occurred after anticoagulants were resumed.
To assess the successful achievement of targeted anticoagulation, we calculated the mean INR and the mean estimated time in therapeutic range (TTR) within groups. The mean INR of all patients in the cohort, the subgroups of patients with and without stroke and the subgroups of patients with ischemic versus hemorrhagic strokes, was all comparable (Table 1) . However, the mean TTR was lower in the group of patients with stroke (54.75%) compared with the total cohort (60.33%) and to the patients without stroke (61.84%). Mean TTR was also slightly lower in patients with ischemic stroke (52.98%) compared with those with hemorrhagic stroke (58.67%; Table 1 ).
To identify risk factors that may influence the occurrence of LVAD-associated stroke, we analyzed the association of many baseline characteristics with the outcome of ischemic or hemorrhagic stroke (Table I in the online-only Data Supplement). The mean INR at the time of stroke was 2.2 (± 0.9), and the level of anticoagulation was not significantly associated with either ischemic stroke (P=0.52) or hemorrhagic stroke (P=0.63). (Figure [A] ). TIA was another strong predictor of ischemic stroke (OR, 3.20; 95% CI, 1.02-10.09; P=0.047) but not hemorrhagic stroke. There was a strong trend toward a statistically significant association between dialysis dependence and hemorrhagic stroke after LVAD placement (OR, 6.31; 95% CI, 0.99-40.47; P=0.052; Figure [B] ). There were also trends toward associations of post-LVAD hemorrhagic stroke with each of the following comorbidities: hypertension, peripheral vascular disease, and COPD.
After excluding the nonsignificant predictors, the final multivariable Cox regression model correlated with post-LVAD ischemic stroke included COPD, serum albumin, RV failure, prior TIA, and hypertension ( Table 2 ). The most significant predictors of post-LVAD ischemic stroke were COPD (hazard ratio, 5.30; P=0.001) and prior TIA (hazard ratio, 4.46; P=0.005). The multivariable model correlated with post-LVAD hemorrhagic stroke included hemodialysis dependence, RV failure, and peripheral vascular disease, but only hemodialysis maintained statistical significance (hazard ratio, 9.57; P=0.005). COPD, serum albumin, RV failure, and prior TIA remained in the multivariable model predicting overall post-LVAD stroke. Interestingly, higher serum 
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albumin and RV failure were protective against post-LVAD ischemic and overall stroke. The overall stroke rate was 0.16 cerebrovascular events per patient-year. For patients suffering a neurovascular complication, the median stroke-free period after LVAD implantation was 32 days (Figure [C] ). The occurrence of stroke was strongly associated with increased mortality (logrank P=0.04; Figure [D] ; Table II in the online-only Data Supplement).
Post-LVAD death was used as a secondary outcome in univariable and multivariable logistic regression models to uncover independent predictors of mortality and to assess the association between post-LVAD stroke and death (Table II in the online-only Data Supplement). In the univariate logistic model, age, chronic kidney disease, and COPD were associated with higher odds of death. However, the strongest univariate associations with mortality were noted for ischemic and hemorrhagic strokes. In the multivariable logistic regression model 
Discussion
As LVADs become a more widely used treatment option for patients with refractory heart failure, 6 ,23 post-LVAD stroke will undoubtedly become an increasingly important cause of morbidity and reduced quality of life in this vulnerable population. 24, 25 A paucity of data exists to guide prognostication based on stroke subtype and associated risk factors. In this study, we distinguished between ischemic and hemorrhagic post-LVAD strokes to evaluate their frequency, association with stroke risk factors, and effect on mortality. In agreement with a recently published study of outcomes in patients with post-LVAD strokes, our patients with hemorrhagic strokes had an increased mortality compared with those with ischemic stroke. 12 One recently published retrospective study reviewing administrative claims on 1813 LVAD patients reported similar increases in mortality for ischemic and hemorrhagic strokes. However, data on out-of-hospital deaths, which the investigators note may overestimate the strength of the association between stroke and mortality, were not available. 19 This is the first study to demonstrate that COPD and dialysis dependence are independently associated with increased risk of post-LVAD stroke. The recently published Rotterdam study demonstrated a large (though not statistically significant) trend toward increased risk of stroke in LVAD patients with a history of COPD, 14 and in non-LVAD patients, a growing body of evidence suggests an increased risk of stroke in COPD patients. 26, 27 The relationship between COPD and stroke is not clearly understood. Recent studies have shown that COPD patients have a higher risk of small-vessel damage and cerebral microbleeds 28, 29 and an increased burden of large-vessel disease and a higher risk of plaque rupture. 27, 30 This relationship may be partially explained by increased systemic inflammation associated with acute COPD exacerbations [31] [32] [33] or aggravated by hypoxia. 27, 34 The correlation may also be partially explained by common shared stroke risk factors like smoking, hypertension, diabetes mellitus, and hyperlipidemia or may be because of an increased risk for postoperative infection, which may increase the risk of stroke. 35, 36 Unlike the Rotterdam study, we did not detect an association of COPD with post-LVAD hemorrhagic strokes. 27 Cerebrovascular disease has been reported to be a major cause of death in dialysis-dependent patients. [37] [38] [39] [40] [41] Our study is also the first to report the increased risk of hemorrhagic stroke in dialysis-dependent patients with an LVAD. There are many chronic kidney disease and dialysis-dependent-specific risk factors, including uremic bleeding diathesis combined with routine anticoagulation during hemodialysis, that could potentially lead to an increased risk of hemorrhagic stroke 37, 42 In addition, dialysis-dependent patients have an increased burden of cerebral microbleeds, 43, 44 which have been correlated with hemorrhagic strokes in a longitudinal study. 45 Given the high mortality among the post-LVAD hemorrhagic stroke patients, our findings suggest that the standard interventions for stroke prevention (antithrombotics and statins) and dialysis delivery (including the use of heparin) may require special consideration in the dialysis-dependent population and warrant further investigation to optimize stroke prevention.
Patients with symptomatic cerebrovascular disease (previous TIA or stroke) are at increased risk of further cerebrovascular events. 46 However, in our study, prior history of stroke did not predict stroke or mortality. The reason for this lack of association is uncertain but may relate to the aggressive antithrombotic regimens used in the LVAD-supported patient population or may simply reflect underpowering. On the other hand, TIA, consistent with the literature, was associated with increased risk of ischemic stroke.
This study was supplemented by retrospective data, and limitations include the potential inaccuracy introduced by retrospective collection. In addition, the number of patients was relatively small, limiting the statistical power of the analysis and the conclusions. Our study did not account for patients who had revascularization procedures such as carotid endarterectomy or stenting that could have decreased the subsequent risk of stroke because these data were not available. We only included outcomes with HM II LVADs in our study, whereas others have reported on stroke rates and risk factors with HeartWare HVAD. 12 Early data on stroke risk with the newest generation continuous-flow LVAD, HeartMate 3, have also been reported. 47 Stroke has been shown to be a devastating complication of LVAD support, increasing morbidity and mortality 3-to 4-fold. These data may be of use to those who care for patients requiring mechanical circulatory support to minimize the risk of ischemic and hemorrhagic strokes. Given the finding of increased risk of ischemic stroke among patients with COPD requiring an LVAD, this subset of patients may warrant a tailored approach to antithrombotic treatment, for example, enforcing a more aggressive regimen of INR monitoring to ensure therapeutic anticoagulation. Similarly, given the increased risk of hemorrhagic stroke associated with dialysis dependence, such patients may benefit from more aggressive INR monitoring to avoid excessive INR values. In addition, careful attention to early evidence of renal dysfunction, minimization of nephrotoxic interventions, and prompt and aggressive management of acute kidney injury to prevent progression to dialysis dependence may forestall this increased risk. Ultimately, analysis of larger cohorts should allow us to develop risk stratification models which might inform clinical decision-making to maximize the benefits and minimize the risks of therapeutic anticoagulation and improve outcomes for patients requiring LVAD support.
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